Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skeletal Muscle Cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Skeletal Muscle Cell. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-003359-33 Sponsor Protocol Number: MABS06 Start Date*: 2023-06-21
    Sponsor Name:MUMC
    Full Title: Assess efficacy of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers
    Medical condition: Mitochondrial myopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10027710 Mitochondrial myopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001730-19 Sponsor Protocol Number: v1-2 Start Date*: 2022-02-24
    Sponsor Name:Medical Univerity of Vienna
    Full Title: Hormones and Muscle – Unravelling the metabolic pathways of endocrine myopathies A translational magnetic resonance spectroscopy and imaging pilot study
    Medical condition: Hypothyroidism Hypoparathyroidism
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005592-13 Sponsor Protocol Number: FERRICHFII Start Date*: 2014-02-27
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: Mechanisms of Exercise Benefit with Intravenous Iron in Chronic Heart Failure: The Ferric Iron in Heart Failure (FERRIC HF) II Trial
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000201-72 Sponsor Protocol Number: 1 Start Date*: 2012-05-11
    Sponsor Name:University of Aberdeen [...]
    1. University of Aberdeen
    2. University of Aberdeen
    Full Title: The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and Therapeutic Potential. Peripheral Arterial Disease
    Medical condition: Peripheral arterial Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003557-15 Sponsor Protocol Number: HMB-ICU Start Date*: 2018-08-31
    Sponsor Name:Guy's and St Thomas NHS Foundation Trust
    Full Title: A Study to Investigate the Effect of β-Hydroxy-β-Methylbutyrate (HMB) on Skeletal Muscle Wasting in Early Critical Illness.
    Medical condition: Critical illness
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10077264 Critical illness PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004149-26 Sponsor Protocol Number: METRIS-HF(EMPA) Start Date*: 2018-06-26
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction
    Medical condition: Heart Failure with reduced ejection fraction (HFrEF and HFmrEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021463-32 Sponsor Protocol Number: IC-01-02-02-007 Start Date*: 2011-02-24
    Sponsor Name:Innovacell Biotechnologie AG
    Full Title: Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-finding clinical study
    Medical condition: Fecal incontinence in female and male patients with external anal sphincter weakness or sphincter damage.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000167639 10016296 Fecal incontinence LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) SI (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002634-16 Sponsor Protocol Number: NL76533.041.21 Start Date*: 2021-08-25
    Sponsor Name:University Medical Center Utrecht
    Full Title: Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic patients with head and neck squamous cell carcinoma
    Medical condition: The IMP will be used to treat locally advanced head and neck squamous cell carcinoma (HNSCC). Patients with low skeletal muscle mass will be randomized between two schedules: 1) weekly 40 mg/m2 cis...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002213-60 Sponsor Protocol Number: GX1001 Start Date*: 2019-01-08
    Sponsor Name:Solid Biosciences Inc.
    Full Title: A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with D...
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-021871-10 Sponsor Protocol Number: IC-01-01-05-004 Start Date*: 2012-04-18
    Sponsor Name:Innovacell Biotechnologie AG - Life Science Center Innsbruck
    Full Title: A multicenter, randomized, double-blinded, parallel-group, placebocontrolled study to assess the efficacy and safety of skeletal muscle-derived cell implantation in female patients with stress urin...
    Medical condition: Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patients
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038359 - Renal and urinary disorders 10066218 Stress urinary incontinence PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004825-17 Sponsor Protocol Number: preTopic17 Start Date*: 2017-12-06
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy
    Medical condition: Parvovirus B19-induced inflammatory cardiomyopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011797-15 Sponsor Protocol Number: IC-01-01-4-003 Start Date*: 2009-12-18
    Sponsor Name:Innovacell Biotechnologie AG
    Full Title: Skeletal muscle-derived cell implantation in female patients with stress urinary incontinence: a multicenter, randomized, parallel-group, placebo-controlled clinical study
    Medical condition: Stress urinary incontinence (SUI) in female patients with predominately intrinsic sphincter deficiency of moderate severity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066218 Stress urinary incontinence LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001656-34 Sponsor Protocol Number: IC-01-01-05-015 Start Date*: 2014-10-01
    Sponsor Name:Innovacell Biotechnologie AG
    Full Title: Skeletal muscle-derived cell implantation in female patients with stress urinary incontinence: a multinational and multicenter open follow-up study
    Medical condition: Stress urinary incontinence (SUI) in female patients of moderate severity (Grade 2 and Grade 3)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038359 - Renal and urinary disorders 10066218 Stress urinary incontinence PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-001825-28 Sponsor Protocol Number: R119513 Start Date*: 2019-09-24
    Sponsor Name: The University of Manchester
    Full Title: Mesoangioblast-mediated exon 51 skipping for genetic correction of dystrophin, based upon a single injection in individual skeletal muscles of five non ambulant patients affected by Duchenne Muscul...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-006967-35 Sponsor Protocol Number: HEME 1.0 Start Date*: 2009-02-11
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für klinische Pharmakologie
    Full Title: The effects of intravenous heme arginate on functional magnetic resonance imaging during ischemia
    Medical condition: ischemia reperfusion injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034578 Peripheral ischemia LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001376-42 Sponsor Protocol Number: IC-01-02-5-009 Start Date*: 2021-10-27
    Sponsor Name:Innovacell AG
    Full Title: Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a phase III, randomized, controlled, double blind, two armed clinical study.
    Medical condition: Fecal incontinence
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10016296 Fecal incontinence LLT
    20.0 100000004856 10055507 Fecal incontinence aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing) BG (Ongoing) PL (Ongoing) CZ (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005399-21 Sponsor Protocol Number: IC-01-02-2-010 Start Date*: 2022-02-14
    Sponsor Name:Innovacell AG
    Full Title: Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a single arm, open label, interventional, follow-up study
    Medical condition: Fecal incontinence (FI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10016296 Fecal incontinence LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001791-19 Sponsor Protocol Number: G300504 Start Date*: 2011-09-22
    Sponsor Name:GTx, Inc.
    Full Title: Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
    Medical condition: Cachexia, muscle wasting in patients with Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025048 Lung cancer non-small cell recurrent LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001792-39 Sponsor Protocol Number: G300505 Start Date*: 2012-01-04
    Sponsor Name:GTx, Inc.
    Full Title: Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemoth...
    Medical condition: Cachexia, muscle wasting in patients with Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025048 Lung cancer non-small cell recurrent LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022150-16 Sponsor Protocol Number: Moxifloxacin Sepsis PEG Start Date*: 2011-01-27
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.klinische Pharmakologie
    Full Title: Determination of Moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients including a pilot phase
    Medical condition: To evaluate feasibility of Moxifloxacin determination in septic patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:31:28 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA